The Asia-Pacific peptide therapeutics market will see a considerable growth of 6.7% during the forecast period. Asia-Pacific is one of the promising regions in the field of peptides. The frequent collaboration of various global and domestic companies through workshops and seminars is also expected to present a new growth opportunity for the Asia-Pacific peptide therapeutics market.
‘AsiaTIDES Oligonucleotide & Peptide Therapeutics’ is expected to take place between November 11 to 13, 2020. It is the only event in Asia that is expected to bring together science, technologies, and partners to accelerate oligonucleotide and peptide molecules to market. It offers separate tracks covering the latest oligonucleotide and peptide development strategies from discovery, nonclinical, clinical, and CMC to late-stage development and commercialization.
A Full Report of Asia-Pacific Peptide Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-peptide-therapeutics-market
Asia-Pacific Peptide Therapeutics Market- Segmentation
By Route of Administration
• Oral
• Parenteral
By Application
• Cancer
• Metabolic Disorder
• Gastrointestinal Disorders
• Central Nervous System Disorders
• Respiratory Disorders
• Others (Kidney Disorder and Autoimmune Disorder)
Asia-Pacific Peptide Therapeutics Market – Segmentation by Geography
• China
• Japan
• India
• Rest of Asia-Pacific
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
